- June 16, 2026Host-response enables rapid assessment of infection type and risk of deterioration in high-consequence infectious disease setting. Sunnyvale, CA, June 16,…
- September 30, 2025Inflammatix cracks the code of sepsis with an AI-powered test that outperforms the standard of care SEPSIS-SHIELD study validates TriVerity™…
- September 4, 2025Publication demonstrates superior analytical performance of TriVerity in assessing patients with suspected acute infection or sepsis Inflammatix, a pioneering host…
- June 10, 2025Seasoned medtech executive joins as hospital adoption accelerates for breakthrough diagnostic in acute infection and sepsis care Sunnyvale, Calif., June…
March 25, 2025The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for…
January 21, 2025
November 11, 2024First interventional study designed to demonstrate the clinical utility of the TriVerity test and its impact on patient management Sunnyvale,…- October 10, 2024Sam Ajizian, MD (Chief Medical Officer), Jamie Lewis (Chief Commercial Officer), and Laura Spencer Garth (General Counsel) Hired to Advance…
October 1, 2024Sunnyvale, Calif., October 1, 2024 — Inflammatix, a pioneering molecular diagnostics company, today presented data demonstrating the high diagnostic and prognostic…- September 12, 2024Fundraise brings lead product, TriVerity™ Test, closer to commercialization following recent submission to FDA. Sunnyvale, Calif., September 12, 2024 — Inflammatix,…
